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Introduction
A major challenge in the pathogenesis of both multiple
myeloma (MM) and monoclonal gammopathy of undeter-
mined significance (MGUS) has been the identification of the
cell of origin of both neoplasias. Monoclonal plasma cells (M-
PC) from patients with MM usually show a low proliferative
capacity as assessed by labeling indices of <0.5%;1 this finding
supports the notion that pre-PC compartments may contain
the proliferative M-PC progenitor. In line with this hypothesis,
circulating peripheral blood cells clonally identical to bone mar-
row M-PC have been recurrently detected in MM.2-7 Apart
from the presence of the malignant IGH gene rearrangement,
these peripheral blood cells have also been found in some
patients to carry karyotypic alterations such as trisomy 11,
del(17p)-, and oncogenic proteins (e.g. IGH-FGFR3, IGH-
MMSET) expressed by CD138+ M-PC.6-8 Moreover, intraclonal
heterogeneity, as assessed through the analysis of the IGHV
gene sequence9 or through the investigation of cytogenetic
alterations10 and gene mutations evaluated by whole exome
sequencing,11 has been reported within the M-PC population,
suggesting that the tumor PC compartment could be continu-
ously repopulated by more than one stem cell. 
There is a growing body of evidence showing the presence
of circulating aberrant PC not only in patients with MM but
also in those with MGUS,12-16 and recent studies have demon-
strated the presence of cells sharing stem cell properties within
the compartment of M-PC.17 However, the question that
remains to be answered is whether or not clonotypic cells are
also identifiable in peripheral blood B-cell subsets, which
would be the “earliest clonotypic cells”. Clonotypic cells were
first identified in a sorted CD19+ fraction2 and the pattern of
somatic hypermutation in the VH regions of the IGH gene sug-
gested that the malignant cell had passed through the germinal
center.18 This was further supported by the detection of periph-
eral blood clonotypic memory B cells in MM patients2,6 and the
finding that in vitro clonogenicity was reduced when memory B
cells were removed.19 In contrast, screening for cells with a pre-
PC phenotype in cell lines,4,19-21 and analysis of the engraftment
of peripheral blood B cells from MM patients into immunode-
ficient mice3,19,22,23 have provided inconsistent findings. In paral-
lel, depletion of B cells by rituximab therapy has not shown
clear beneficial clinical effects in MM, except in a small fraction
of patients with CD20+ PC,24,25 and evaluation of the clonal hier-
archy in light chain-secreting myeloma did not detect clono-
typic circulating cells, except in one patient showing peripheral
blood infiltration by malignant PC.26 One explanation for these
discrepant results is a simple technical pitfall: the B cells ana-
©2013 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.092817
The online version of this article has a Supplementary Appenix.
Manuscript received on June 6, 2013. Manuscript accepted on July 17, 2013.
Correspondence: orfao@usal.es
The B-cell compartment in which multiple myeloma stem cells reside remains unclear. We investigated the poten-
tial presence of mature, surface-membrane immunoglobulin-positive B lymphocytes clonally related to the tumor
bone marrow plasma cells among different subsets of peripheral blood B cells from ten patients (7 with multiple
myeloma and 3 with monoclonal gammopathies of undetermined significance). The presence of clonotypic
immunoglobulin heavy chain gene rearrangements was determined in multiple highly-purified fractions of periph-
eral blood B-lymphocytes including surface-membrane IgM+ CD27- naïve B-lymphocytes, plus surface-membrane
IgG+, IgA+ and IgM+ memory CD27+ B cells, and normal circulating plasma cells, in addition to (mono)clonal plasma
cells, by a highly-specific and sensitive allele-specific oligonucleotide polymerase chain reaction directed to the
CDR3 sequence of the rearranged IGH gene of tumor plasma cells from individual patients. Our results showed
systematic absence of clonotypic rearrangements in all the different B-cell subsets analyzed, including M-compo-
nent isotype-matched memory B-lymphocytes, at frequencies <0.03 cells/mL (range: 0.0003-0.08 cells/mL); the only
exception were the myeloma plasma cells detected and purified from the peripheral blood of four of the seven
myeloma patients. These results indicate that circulating B cells from patients with multiple myeloma and mono-
clonal gammopathies of undetermined significance are usually devoid of clonotypic B cells while the presence of
immunophenotypically aberrant myeloma plasma cells in peripheral blood of myeloma patients is a relatively fre-
quent finding.
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ABSTRACT
lyzed could be contaminated in some cases by circulating
PC. In fact, to the best of our knowledge, no highly sensi-
tive molecular analysis of different compartments of highly
purified circulating B cells specifically devoid of contaminat-
ing circulating M-PC has been performed so far, to confirm
or rule out the presence of clonotypic B cells in MM and
MGUS.
Here, we investigated the presence of circulating B cells
which would be clonally related to the M-PC in patients
with MM and MGUS, using an allele-specific oligonu-
cleotide polymerase chain reaction (ASO-PCR) technique
aimed at sensitive and specific detection of IGHVDJmono-
clonal gene sequences unique to the tumor cells of individ-
ual patients. This analysis was performed in multiple, differ-
ent, highly-purified, maturation-associated subsets of
peripheral blood B cells (SmIgM+/CD27- naïve, isotype non-
switched SmIgM+ and isotype-switched SmIgG+ and SmIgA+
memory B-lymphocytes, and PC) from a group of seven
patients with MM and three with MGUS.
Methods
Patients and samples
Ten patients (7 with MM and 3 with MGUS) diagnosed with
monoclonal gammopathies27 were studied. In all cases, paired bone
marrow and peripheral blood samples were collected at diagnosis
for further immunophenotypic characterization, isolation, and
molecular analysis of M-PC and other B-cell subsets, after
informed consent was given by each individual. The study was
approved by the Ethics Committee of the Cancer Research Center
of the University of Salamanca, (Salamanca, Spain) and it followed
the Helsinki Declaration protocol. The most relevant clinical and
biological characteristics of the patients studied are summarized in
Online Supplementary Table S1.
Multiparameter flow cytometry immunophenotypic 
studies and cell purification
Multiparameter flow cytometry immunophenotypic studies
were performed as recently described28-31 (and detailed in the Online
Supplementary Methods) in both bone marrow and peripheral blood
samples. Fluorescence-activated cell sorting (FACS) was used to
purify bone marrow M-PC as well as peripheral blood B-cell sub-
sets and normal PC (N-PC); whenever present, circulating M-PC
were also purified. The purity of the sorted M-PC and the multiple
peripheral blood normal B-cell subsets was systematically ≥98%,
and only those peripheral blood B-cell fractions which showed no
contamination (<0.01%) by circulating peripheral blood M-PC
were included in the study; all other fractions were not tested
(Table 1).
Analysis of IGH gene rearrangements of bone marrow
monoclonal plasma cells and CDR3 sequencing
The malignant IGH gene rearrangement was identified in
genomic DNA according to the BIOMED-2 protocol32,33 slightly
modified to amplify the specific monoclonal complete VH-JH and
incomplete DH-JH. PCR amplified products were identified by
high-resolution capillary electrophoresis in an automated ABI
PRISM 3130 Avant sequencer, using GENEMAPPER 3.1 software
(AB). Clonal PCR products were purified, sequenced and identified
as previously reported.34 Once the segments had been identified,
the N-region was highlighted for ASO-primer design due to its
high specificity for each individual rearrangement, as previously
described.35
A qualitative ASO-PCR with the CDR3 specific primer and its
respective 6-FAM-labeled IGH JH primer, was carried out on puri-
fied bone marrow M-PC from each patient; purified peripheral
blood B cells from healthy donors were studied in parallel as neg-
ative controls.  If a single (clonal) peak was detected in a sample, it
was sequenced to confirm that the sets of primers were really spe-
cific. In order to assess the sensitivity of each patient-specific set of
primers used in the ASO-PCR assay (e.g.: the lowest number of
cells detected), ASO-PCR analyses were carried out in multiple
tubes containing serial dilutions of one or more previously purified
bone marrow M-PC from individual patients (see Online
Supplementary Methods for a more detailed description). 
Allele-specific oligonucleotide polymerase chain reaction
analysis of purified peripheral blood subpopulations 
of B cells and plasma cells 
DNA was extracted from pre-defined numbers of highly-puri-
fied peripheral blood B-cell and PC subsets. ASO-PCR conditions
were as described above; all purified cells from each cell compart-
ment from each patient were analyzed by ASO-PCR (7 to 10 ASO-
PCR replicates/patient). Clonotypic B cells were defined as being
present within a specific B-cell or PC compartment when two or
more replicates were found to be positive. For every sample, DNA
quality was evaluated by a control according to the BIOMED-2
protocols.32
Results
Distribution of different subsets of B-lymphocytes 
and plasma cells in the peripheral blood of patients 
with multiple myeloma and monoclonal gammopathy 
or undetermined significance 
The following subsets of peripheral blood B cells and PC
were identified:29,31 naïve (CD10- CD19+ CD20+ CD27-
CD38-) and memory (CD10- CD19+ CD20+ CD27+ CD38-)
B-lymphocytes plus normal circulating PC (CD10- CD19+
CD20- CD27++ CD38++). Peripheral blood memory B-lym-
phocytes were further subdivided into switched SmIgA+,
SmIgG+, and non-switched SmIgM+ cells. In four of the seven
MM patients (cases #3, #5, #6 and #7), peripheral blood cir-
culating M-PC with restricted CyIgλ or CyIgκ expression
were also identified as clearly different from N-PC based on
differential expression of CD38, CD19, CD45, and light
scatter.26,29
Overall, no statistically significant differences (P>0.05,
Mann-Whitney U test) were observed in the distribution of
circulating B cells and PC between MM and MGUS patients
(Figure 1). This was the case for total B cells (113±15 versus
83±71 cells/mL), naïve (83±11 versus 53±56 cells/mL) as well
as total memory B cells (30±10 versus 22±16 cells/mL) and
their SmIgM+ (9±4 versus 9±6 cells/mL), SmIgG+ (14±2 versus
4±2 cells/mL), and SmIgA+ (12±1 versus 6±4 cells/mL) subsets,
and also N-PC (0.7±0.4 versus 1.2±1.5 cells/mL) (Figure 1). In
contrast, M-PC were found at frequencies >8.0 cells/mL
(range: 0.08-29.8 cells/mL) in four of the seven MM patients,
but not in the three MGUS cases (although we had detected
them in up to 21% of a larger series of MGUS cases16)
(P<0.05; Figure 1). Of note, all FACS-purified peripheral
blood B-cell subsets (naïve and memory B-lymphocytes)
and N-PC showed a normal protein expression profile,
including a normal polyclonal Igκ versus Igλ light chain ratio,
while the M-PC compartment systematically showed an
aberrant immunophenotype associated with monoclonal
light chain restriction (either CyIgκ+ or CyIgλ+) profile.
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Sensitivity of the molecular assays
The sensitivity assays performed were aimed at defining
the minimum number of clonotypic M-PC required for a
positive result and at establishing the sensitivity of the
ASO-PCR assay over a polyclonal background. The first set
of experiments consistently showed the ability to systemat-
ically detect a (clonal) patient-specific IGH gene rearrange-
ment peak whenever ≥5 clonotypic M-PC were present in
the sample, for all ten patients analyzed; in three of the
seven patients tested (cases #MM1, #MM2, #MGUS3) the
sensitivity was even higher since patient-specific IGH
CDR3 gene rearrangements were detected once a single M-
PC was present in the sample. Regarding the ability to
detect clonotypic M-PC over a background of polyclonal B
cells, sensitivity from dilution experiments was systemati-
cally <10-3, ranging between <10-3 to <10-5 (from 0.2% to
0.001% M-PC cells/total B cells) (Online Supplementary Table
S2), as illustrated in Figure 3 for one of the cases studied. 
The sensitivity of the assay varied per patient for the dif-
ferent cell fractions from <0.08 to <0.0003 cells/mL of
peripheral blood (i.e. <80 to <0.3 cells/mL), according to:
the sensitivity and reproducibility of the assay; the number
of purified peripheral blood B cells and PC analyzed; and
the distribution of the subpopulation (e.g. absolute count) in
the peripheral blood of each individual patient at the
moment the sample was collected (Table 1).
Frequency of clonotypic cells in highly-purified peripheral
blood subsets of circulating B cells and plasma cells  
The search for the presence of clonotypic cells was per-
formed on highly purified peripheral blood naïve B-lym-
phocytes, switched SmIgA+ and SmIgG+, as well as non-
switched SmIgM+ memory B cells and N-PC, present at vari-
able numbers in the peripheral blood of each of the ten
patients with monoclonal gammopathies (Table 1). In addi-
tion, circulating M-PC from four MM patients in whom
these cells were detected at frequencies of 0.79%, 0.09%,
0.03% and 0.17% of all peripheral blood nucleated cells
(absolute M-PC count of 29.8, 0.7, 0.08, and 6.1 cells/mL,
respectively) were also purified and analyzed. Overall, no
cells carrying clonotypic IGH gene rearrangements were
detected among the phenotypically normal B-cell subsets or
N-PC from any of the MM (0/7) or MGUS (0/3) patients
analyzed (Table 1). For Ig-switched memory B cells sharing
the same Ig heavy chain isotype as bone marrow M-PC, a
sensitivity of between <6 cells/mL and <24 cells/mL of
peripheral blood (IgG+ MM) and of <9 cells/mL (IgA+ MM)
of peripheral blood was reached. As expected, analysis of
peripheral blood M-PC confirmed the presence of clonotyp-
ic IGH gene rearrangements identical to those identified in
the corresponding (paired) bone marrow M-PC, in all repli-
cates of purified M-PC analyzed (Table 1 and Figure 2).
Discussion
Since the pioneering experiments which used anti-idio-
typic antibodies to track the oncogenic event in MM
throughout B-cell ontogeny,36,37 controversial results have
been reported in the literature regarding the B-cell compart-
ment in which the potential myeloma stem cell resides. For
more than a decade now, it has been generally accepted that
circulating CD19+ B-lymphocytes from MM patients could
contain cells that carry clonotypic rearrangements identical
to those of MM-PC.2-7 However, the frequency and nature
of such clonally-related cells remains a matter of debate.
Table 1. Frequency and absolute counts of clonotypic cells detected in different B-cell and PC subsets present in the peripheral blood of patients with MGUS
(n=3) or MM (n=7).
Subsets of B-lymphocytes PC Subsets      
Case ID  / Isotype Total Naïve Total memory SmIgM+ SmIgG+ SmIgA+ N-PC M-PC
of the M-Component B-lymphocytes B-lymphocytes B-lymphocytes memory memory memory
B cells B cells B cells
MGUS 1 <0.014 <0.004 <0.0105 <0.008 <0.015 <0.015 <0.0030 ND
IgG+ (<0.06%) (<0.007%) (<0.05%) (<0.01%) (<0.2%) (<0.1%) (<0.5%)
MGUS 2 <0.019 NT <0.0064 <0.001 <0.009 <0.008 <0.0058 ND
IgG+ (<0.02%) (<0.01%) (<0.04%) (0.08%) (<0.08%) (<0.5%)
MGUS 3 <0.018 NT <0.0041 <0.002 <0.011 <0.005 <0.00033 ND
IgG+ (<0.02%) (<0.02%) (0.05%) (<0.2%) (<0.06%) (<0.08%)
MM 1 <0.02 <0.017 <0.0078 <0.006 <0.006 <0.048 <0.0031 ND
IgG+ (<0.01%) (<0.1%) (<0.04%) (0.06%) (<0.1%) (<0.4%) (<0.8%)
MM 2                        <0.03 <0.037 <0.0178 NT NT NT NT ND
IgA+ (<0.03%) (<0.01%) (<0.05%)
MM 3 <0.015 <0.007 <0.037 NT <0.024 <0.011 <0.0042 29
IgG+ (<0.01%) (<0.01%) (<0.1%) (<0.5%) (<0.2%) (<0.6%) (100%)
MM 4 <0.03 <0.035 <0.026 NT <0.012 <0.009 <0.00029 ND
IgA+ (<0.11%) (<0.3%) (<0.3%) (<0.6%) (<0.8%) (<0.5%)
MM5 <0.03 <0.077 <0.013 <0.013 NT NT <0.024 0.7
IgG+ (<0.03%) (<0.1%) (<0.05%) (<0.08%) (<14%) (100%)
MM6 <0.02 <0.025 <0.022 <0.034 NT NT <0.037 0.08
IgA+ (<0.02%) (<0.02%) (<0.09%) (<0.2%) (<8%) (100%)
MM7 <0.006 <0.005 <0.01 <0.009 NT NT <0.013 6.1
IgG+ (<0.01%) (<0.01%) (<0.03%) (<0.3%) (<0.2%) (100%)
Results expressed as number of cells/mL and percentage of peripheral blood nucleated cells. The sensitivity of the assay was calculated based on the number of cells purified for each cell subset
and its distribution in peripheral blood. ND: not detected; NT: not tested; MM: multiple myeloma; MGUS: monoclonal gammopathy of undetermined significance.
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While some groups suggested that the majority of circulat-
ing B-lymphocytes would belong to the malignant clone,2,3
others could not confirm these preliminary observations
and reported that, if present, circulating clonotypic B cells
would constitute a minor population of all peripheral blood
leukocytes.38,39
Important advances have been achieved in molecular as
well as in cell purification techniques (e.g. improved exclu-
sion of cell doublets and sorting efficiency, standard usage
of ≥8-color experiments for better definition of the cell sub-
populations of interest and exclusion of unwanted cells).
Based on such technological advances we decided to revisit
in the present study the detection of clonally related B cells
in the peripheral blood of patients with monoclonal gam-
mopathies. For this purpose we used a highly-sensitive
approach. First, an eight-color multiparameter flow cytom-
etry technique was used for the identification of the distinct
subsets of circulating peripheral blood B cells and PC, in
combination with multiparameter sorting of highly puri-
fied, non-contaminated, cell fractions corresponding to such
subsets of peripheral blood naïve and memory B-lympho-
cytes (including SmIgM+, SmIgA+ and SmIgG+ memory B cells),
in addition to N-PC and, whenever present, also M-PC. In a
second step, molecular detection of clonotypic B cells was
performed on DNA from the purified B-cell subsets and PC
using a highly-sensitive ASO-PCR technique specifically
designed for the detection of clonotypic B cells of individual
patients.
Our results showed systematic absence of clonotypic
IGH gene rearrangements in all different B-cell subsets ana-
lyzed, including M-component isotype-matched memory
B-lymphocytes; the only exception were the M-PC detect-
ed and purified from the peripheral blood of four MM
patients. In line with these observations, no altered patterns
of protein expression were found in any of the purified frac-
tions of naïve and memory B-lymphocytes or N-PC, all
such cell subsets also showing a normal polyclonal Igκ ver-
sus Igλ light chain ratio, except M-PC. 
Considering the sensitivity of the assay used, the number
of cells analyzed and the volume of blood investigated, it
seems unlikely that circulating clonotypic B-lymphocytes
are present in MM and MGUS patients at frequencies
between >6 and 30 cells/mL (<1 cell in between 33 and 166
mL of peripheral blood). Even more, when we specifically
consider the absence of clonotypic B cells among the com-
partment of memory B cells (as the most susceptible to con-
taining the myeloma stem cell) the frequency would go
down to between <4.1 and <37 cells/mL. 
Overall, the sensitivity of the approach used here is far
beyond that of the techniques used in most previously
reported studies in which the presence of clonotypic B-lym-
phocytes was reported. In this regard, the discrepancies
observed between our and other studies cannot be due to
selection of patients12 since almost all our MM patients had
symptomatic MM and they had not received prior therapy
for their disease. We did confirm the presence of circulating
M-PC at relatively high numbers in the peripheral blood of
the majority of MM patients (range: 80 to 29,800 cells/mL),
in line with previous observations by our and other
groups.12-16 This frequency is lower than that reported in ear-
lier studies for circulating clonotypic B cells (range: 10,000
to 610,000 cells/mL).3 It is worth noting that, in a substantial
number of these previous studies, total peripheral blood B
cells were used to search for clonotypic IGH gene
rearrangements and contamination by M-PC (e.g. due to
doublet formation or altered time delay in sorting experi-
ments) was not systematically excluded. In this regard, we
have recently confirmed contamination of peripheral blood
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Figure 1. Distribution
of B-lymphocytes and
plasma cells and
their subsets in the
peripheral blood of
patients with MGUS
(n=3, white boxes)
and MM (n=7; black
boxes). N-PC: normal
plasma cells; M-PC:
(mono)clonal plasma
cells. Boxes extend
from the 25th to the
75th percentiles; the
line in the middle and
the vertical lines rep-
resent median values
and both the 10th and
90th percentiles,
respectively. The
Mann–Whitney U test
was used to estimate
the statistical signifi-
cance of differences
observed. *P<0.05
vs. MGUS. 
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Figure 2. Example of the results
of molecular analysis of clonotyp-
ic B cells and PC in purified B-cell
and PC subsets from the periph-
eral blood (PB) of a MM patient
(case #MM3). As shown, circulat-
ing (mono)clonal plasma cells
(M-PC) are the only compartment
of PB B cells from this patient
that showed a clonal CDR3 gene
rearrangement signature similar
to that of bone marrow M-PC
from the same patient (A). The
quality of the DNA samples from
all FACS-purified PB B-cell and PC
subsets of each individual patient
was analyzed in parallel for a con-
trol gene with PCR primers direct-
ed to the human thromboxane
synthase gene (TBXAS1) (B). 
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B cells by M-PC through re-analysis of a frozen sample
from a patient who had been previously reported to carry
clonotypic non-switched B cells.26 This could contribute to
explain, at least in part, the discrepancies observed between
our and other studies, even when our approach dramatical-
ly increased the sensitivity and specificity of the analysis. In
contrast, our results fully support recent findings by Kim et
al.21 in SCID mice previously engrafted subcutaneously
with fetal human bone, showing that only the MM-PC
compartment was able to give rise to clonally-related,
patient-specific MM cells in (two) serial transplants;
although plasmablasts and B cells were also able to engraft
in those mice, their capacity was limited to the first xeno-
transplantation and these compartments could not give rise
to any cell with the same patient-specific MM molecular
signature.21 Alternatively, it is possible that the tumor pre-
cursor would circulate only at the earlier stages of disease to
fill/feed the bone marrow niches, giving rise to tumor PC.
However, this seems unlikely since different peripheral
blood B-cell compartments from MGUS patients analyzed
here were also found to be devoid of clonotypic cells with
the same IGH gene rearrangement as bone marrow M-PC. 
Altogether, our results suggest that if peripheral blood
clonal B-lymphocytes exist in MM and MGUS, they are
present at extremely low frequencies in most patients, and
would not explain the dissemination throughout the bone
marrow during active/progressive disease, as observed in
many symptomatic MM patients. Conversely, since circu-
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Figure 3. Example of a dilution experiment performed and analyzed by GeneScanning for one representative MM patient (case #MM6). To
evaluate the sensitivity of the ASO-PCR assay for this patient, DNA from M-PC obtained from the bone marrow (BM) was diluted into polyclonal
DNA obtained from FACS-purified peripheral blood (PB) B cells from a healthy donor. Numbers between brackets indicate the M-PC:normal
B-cell dilution factor.
7000
6000
5000
4000
3000
2000
1000
0
7000
6000
5000
4000
3000
2000
1000
0
7000
6000
5000
4000
3000
2000
1000
0
7000
6000
5000
4000
3000
2000
1000
0
7000
6000
5000
4000
3000
2000
1000
0
40 80 120
BM M-PC/polyclonal B cells 
(10-2)
BM M-PC/polyclonal B cells 
(10-3)
BM M-PC/polyclonal B cells 
(10-4)
BM M-PC/polyclonal B cells 
(10-5)
Polyclonal B cells 
40 80 120
40 80 120
40 80 120
40 80 120
Base pairs
Fl
uo
re
sc
en
ce
 in
te
ns
ity
lating M-PC were frequently detected at rather higher num-
bers, it could be hypothesized that the myeloma clonogenic
cell could be part of the malignant PC compartment which
is able to re-circulate and spread the disease. In line with
this latter hypothesis recent findings indicate that circulat-
ing peripheral blood M-PC from both MM and MGUS
patients display a slightly more immature immunopheno-
type with lower expression of CD138,16 a phenotypic fea-
ture of M-PC that has been associated with increased clono-
genic potential and other myeloma stem cell features.4,19
Furthermore, circulating peripheral blood M-PC are also fre-
quently detected in early phases of the disease including
MGUS and smoldering MM.12,16 Further studies, in which
the clonogenic potential of peripheral blood M-PC is com-
pared with that of bone marrow tumor cells, are required to
validate this hypothesis.
In summary, based on a sensitive and well-controlled
approach, in this study we failed to demonstrate the pres-
ence of circulating clonotypic B cells in the peripheral
blood of patients with MM or MGUS, outside the com-
partment of immunophenotypically aberrant clonal PC
detected in a substantial fraction of MM patients. These
findings suggest that tumor dissemination in monoclonal
gammopathies is more likely to be related to the periph-
eral blood compartment of circulating M-PC than to other
populations of less differentiated naïve and memory B-
lymphocytes.
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